07:41 AM EST, 02/23/2026 (MT Newswires) -- Blackstone Life Sciences (BX) said Monday it established a research financing agreement to advance the clinical development of bleximenib, an investigational drug to treat acute myeloid leukemia.

Blackstone and Johnson & Johnson ( JNJ ) will jointly finance a portion of current and upcoming trials evaluating bleximenib, the company said.

Bleximenib is an oral menin inhibitor that works by disrupting a pathway that drives leukemic cell growth, the company said.